期刊文献+

系统性红斑狼疮的肺损害 被引量:5

Pulmonary damage associated with systemic lupus erythematosus
原文传递
导出
摘要 系统性红斑狼疮(SLE)的特征是产生致病性自身抗体和免疫复合物,导致多器官受累。肺损害是其常见的并发症,包括胸膜疾病、急性狼疮性肺炎、间质性肺疾病、弥漫性肺泡出血、肺栓塞、肺动脉高压、呼吸道疾病、肺萎缩综合征、肺恶性肿瘤和感染等。临床表现从无症状(如少量胸腔积液)到威胁生命的疾病(如急性狼疮性肺炎或弥漫性肺泡出血)。根据肺部受累类型和严重程度,使用糖皮质激素、免疫抑制剂、血浆置换以及干细胞治疗。治疗过程中需警惕免疫抑制剂本身所致肺损害。 Systemic lupus erythematosus(SLE)is an autoimmune rheumatic disease characterized by the production of pathogenic autoantibodies and immune complexes,leading to multiple organ involvement. Lung damage is a common complication,including pleural disease,acute lupus pneumonitis,interstitial lung disease,diffuse alveolar hemorrhage,pulmonary embolism,pulmonary hypertension,airway disease,shrinking lung syndrome,lung cancer and infection,etc.Conditions can range mostly from asymptomatic(such as in mild cases of pleural effusion)to life-threatening disease(such as in acute lupus pneumonitis or diffuse alveolar hemorrhage). According to the type and severity of lung involvement,glucocorticoids,immunosuppressants,plasma exchange,and stem cell therapy are used. In the course of treatment,it is necessary to guard against lung damage caused by immunosuppressive agents.
作者 杨吉娟 池淑红 YANG Ji-juan;CHI Shu-hong(Department of Rheumatology and Immunology,General Hospital of Ningxia Medical University,Yinchuan 750004,China)
出处 《中国实用内科杂志》 CAS CSCD 北大核心 2021年第9期749-752,756,共5页 Chinese Journal of Practical Internal Medicine
基金 国家自然科学基金(81860132)。
关键词 系统性红斑狼疮 肺损害 急性狼疮性肺炎 间质性肺病 弥漫性肺泡出血 肺动脉高压 systemic lupus erythematosus lung damage acute lupus pneumonitis interstitial lung disease diffuse alveolar hemorrhage pulmonary arterial hypertension
  • 相关文献

参考文献1

二级参考文献16

  • 1季颖群,张卓莉,陆慰萱.结缔组织病相关肺动脉高压的临床分析[J].中华内科杂志,2006,45(6):467-471. 被引量:35
  • 2杨宁,赵成,刘布骏,孙凌云.结缔组织病并发肺动脉高压110例临床分析[J].中华风湿病学杂志,2007,11(9):552-555. 被引量:19
  • 3Li M, Zhang W, Leng X, et al. Chinese SLE Treatment and Research group [CSTAR) registry: I. Major clinical characteristics of Chinese patients with systemic lupus erythematosus[J]. Lupus, 2013, 22(11): 1192-1199. 被引量:1
  • 4Chung L, Liu J, Parsons L, et al. Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL[J]. Chest, 2010, 138(6): 1383-1394. 被引量:1
  • 5Hao YJ, Jiang x, Zhou W, et al. Connective tissue disease-associated pulmonary arterial hypertension in Chinese patients[J].Eur Respir J, 2014, 44(4): 963-972. 被引量:1
  • 6Rabinovitch M. Molecular pathogenesis of pulmonary arterial hypertension[J]. J Clin Invest, 2012, 122(12): 4306-4313. 被引量:1
  • 7Tuder RM, Abman SH, Braun T, et al. Development and pathology of pulmonary hypertension[J]. J Am Coll Cardiol, 2009, 54(1 Suppl): S3-S9. 被引量:1
  • 8Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension[J]. Eur Heart J, 2009, 30(20): 2493-2537. 被引量:1
  • 9Jing zc, Strange G, Zhu XY, et al. Efficacy3 safety and tolerability of bosentan in Chinese patients with pulmonary arterial hypertension[J].J Heart Lung Transplant, 2010, 29(2): 150-156. 被引量:1
  • 10Denton CP, Humbert M, Kubin L, et al. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions[J]. Ann Rheum Dis, 2006, 65( 10): 1336-1340. 被引量:1

共引文献5

同被引文献68

引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部